{"url_path":"/sec/derm/8-k/2026-06-26/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"8-K","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-077888-index.html","accession_number":"0001104659-26-077888","cik":"0001867066","ticker":"DERM","issuer_name":"Journey Medical Corp","edgar_url":"https://www.sec.gov/Archives/edgar/data/1867066/0001104659-26-077888-index.html","primary_entity_key":"0001867066","primary_entity_name":"Journey Medical Corp"},"word_count":275,"has_tables":true,"body_markdown":"false\n0001867066\n\n0001867066\n\n2026-06-24\n2026-06-24\n\niso4217:USD\n\nxbrli:shares\n\niso4217:USD\n\nxbrli:shares\n\n \n\n \n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**WASHINGTON, D.C. 20549**\n\n \n\n**FORM 8-K**\n\n \n\n**CURRENT REPORT**\n\n**Pursuant to Section 13 or 15(d) of the**\n\n**Securities Exchange Act of 1934**\n\n \n\nDate of report (Date of earliest event reported):\n**June 24, 2026**\n\n \n\n**Journey Medical Corporation**\n\n(Exact Name of Registrant as Specified in Charter)\n\n \n\nDelaware \n001-41063 \n47-1879539\n\n(State or Other Jurisdiction\nof Incorporation) \n(Commission File Number) \n(IRS Employer Identification No.)\n\n \n\n**9237 E Via de Ventura Blvd., Suite 105**\n\n**Scottsdale, AZ 85258**\n\n(Address of Principal Executive Offices)\n\n \n\n**(480****)\n434-6670**\n\n(Registrant’s telephone number, including area code)\n\n \n\nCheck the appropriate box below if the Form\n8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:\n\n \n\n¨Written communications pursuant to Rule 425 under the Securities\nAct.\n\n  \n\n¨Soliciting material pursuant to Rule 14a-12 under the Exchange\nAct.\n\n  \n\n¨Pre-commencement communications pursuant to Rule 14d-2b under\nthe Exchange Act.\n\n  \n\n¨Pre-commencement communications pursuant to Rule 13e-4(c) under\nthe Exchange Act.\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\n**Title\nof each class**\n**Trading\nSymbol(s)**\n**Name\nof each exchange on which registered**\n\nCommon Stock\nDERM\nNasdaq Capital Market\n\n \n\nIndicate by check mark whether the\nregistrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or\nRule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).  x\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying\nwith any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨"}